BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32463293)

  • 1. Focal nodular marrow hyperplasia: Imaging features of 53 cases.
    Rajakulasingam R; Saifuddin A
    Br J Radiol; 2020 Aug; 93(1112):20200206. PubMed ID: 32463293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of in-phase and opposed-phase T1W gradient echo and T2W fast spin echo dixon chemical shift imaging for the assessment of non-neoplastic, benign neoplastic and malignant marrow lesions.
    Saifuddin A; Shafiq H; Malhotra K; Santiago R; Pressney I
    Skeletal Radiol; 2021 Jun; 50(6):1209-1218. PubMed ID: 33196854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anomalous signal intensity increase on out-of-phase chemical shift imaging: a manifestation of marrow mineralisation?
    van Vucht N; Santiago R; Pressney I; Saifuddin A
    Skeletal Radiol; 2020 Aug; 49(8):1269-1275. PubMed ID: 32198527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of T1-weighted turbo spin echo and out-of-phase T1-weighted gradient echo Dixon MRI for the assessment of intra-medullary length of appendicular bone tumours.
    Saifuddin A; Santiago R; van Vucht N; Pressney I
    Skeletal Radiol; 2021 May; 50(5):993-1005. PubMed ID: 33078239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Simonitsch-Klupp I; Raderer M; Mayerhoefer ME
    Acad Radiol; 2018 Apr; 25(4):453-460. PubMed ID: 29199055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow magnetic resonance imaging: physiologic and pathologic findings that radiologist should know.
    Chiarilli MG; Delli Pizzi A; Mastrodicasa D; Febo MP; Cardinali B; Consorte B; Cifaratti A; Panara V; Caulo M; Cannataro G
    Radiol Med; 2021 Feb; 126(2):264-276. PubMed ID: 32557107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of in-phase and out-of-phase chemical shift MRI in differentiation of non-neoplastic versus neoplastic benign and malignant marrow lesions.
    van Vucht N; Santiago R; Pressney I; Saifuddin A
    Br J Radiol; 2021 Mar; 94(1119):20200710. PubMed ID: 33571012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole body MRI with qualitative and quantitative analysis of DWI for assessment of bone marrow involvement in lymphoma.
    Balbo-Mussetto A; Saviolo C; Fornari A; Gottardi D; Petracchini M; Macera A; Lario CV; Gallo T; Tarella C; Cirillo S
    Radiol Med; 2017 Aug; 122(8):623-632. PubMed ID: 28421406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing imaging features between spinal hyperplastic hematopoietic bone marrow and bone metastasis.
    Shigematsu Y; Hirai T; Kawanaka K; Shiraishi S; Yoshida M; Kitajima M; Uetani H; Azuma M; Iryo Y; Yamashita Y
    AJNR Am J Neuroradiol; 2014 Oct; 35(10):2013-20. PubMed ID: 24948497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-phase and opposed-phase Dixon chemical shift imaging for the assessment of skeletal marrow lesions: comparison of measurements from longitudinal sequences to those from axial sequences.
    Saifuddin A; Ali M; Santiago R; Pressney I
    Br J Radiol; 2024 Mar; 97(1156):828-833. PubMed ID: 38321150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET vs. chemical shift MR imaging in differentiating intertrabecular metastasis from hematopoietic bone marrow hyperplasia.
    Oki N; Ikebe Y; Koike H; Ideguchi R; Niino D; Uetani M
    Jpn J Radiol; 2021 Nov; 39(11):1077-1085. PubMed ID: 34101119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of Vertebral Metastases From Focal Hematopoietic Marrow Depositions on MRI: Added Value of Proton Density Fat Fraction.
    Jung Y; Jeon SW; Kwack KS; Yun JS; Lee HD; Park S
    AJR Am J Roentgenol; 2021 Mar; 216(3):734-741. PubMed ID: 33405947
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using
    Hao B; Zhao L; Luo NN; Ruan D; Pang YZ; Guo W; Fu H; Guo XY; Luo ZM; Wu J; Chen HJ; Wu H; Sun L
    BMC Cancer; 2018 Nov; 18(1):1192. PubMed ID: 30497426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.